Progressive myoclonus epilepsy associated with neuroserpin inclusion bodies (neuroserpinosis)

Epileptic Disorders

Volumn 18, Issue , 2016, Pages S103-S110

  Roussel, Benoit D ^a,b   Lomas, David A ^a   Crowther, Damian C ^c,d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITÉ DE CAEN   (France)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d MEDIMMUNE   (United States)

Author keywords

conformational disease; dementia; familial progressive myoclonic epilepsy; FENIB; neuroserpin; progressive myoclonus epilepsies; protease inhibitor; serpinopathy; serpins

Indexed keywords

NEUROSERPIN;

BRAIN DISEASE; CELL INCLUSION; COGNITIVE DEFECT; DEMENTIA; DISEASE ASSOCIATION; DISEASE COURSE; FAMILY HISTORY; GENE; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MYOCLONUS EPILEPSY; NEUROSERPIN GENE; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; DEMYELINATING DISEASE; GENETICS; PATHOPHYSIOLOGY;

EPILEPSIES, MYOCLONIC; HEREDODEGENERATIVE DISORDERS, NERVOUS SYSTEM; HUMANS;

EID: 84994189031     PISSN: 12949361     EISSN: 19506945     Source Type: Journal    
DOI: 10.1684/epd.2016.0847     Document Type: Review

References (46)

1. Alvarez V, Rossetti AO, Papavasileiou V, Michel P. Acute seizures in acute ischemic stroke: does thrombolysis have a role to play? J Neurol 2013; 260: 55–61.
2. Baron A, Montagne A, Cassé F, et al. NR2D-containing NMDA receptors mediate tissue plasminogen activator-promoted neuronal excitotoxicity Cell Death Differ 2010; 17: 860–871.
3. Belorgey D, Crowther DC, Mahadeva R, Lomas DA. Mutant neuroserpin (S49P) that causes familial encephalopathy with neuroserpin inclusion bodies is a poor proteinase inhibitor and readily forms polymers. in vitro J Biol Chem 2002; 277: 17367–17373.
4. Belorgey D, Sharp LK, Crowther DC, Onda M, Johansson J, Lomas DA. Neuroserpin portland (Ser52Arg) is trapped as an inactive intermediate that rapidly forms polymers: implications for the epilepsy seen in the dementia FENIB. Eur J Biochem 2004; 271: 3360–3367.
5. Belorgey D, Irving JA, Ekeowa UI, et al. Characterisation of serpin polymers and in vitro and in vivo. Methods 2011; 53: 255–266.
6. Bradshaw CB, Davis RL, Shrimpton AE, et al. Cognitive deficits associated with a recently reported familial neurodegenerative disease: familial encephalopathy with neuroserpin inclusion bodies. Arch Neurol 2001; 58: 1429–1434.
7. Carrell RW, Lomas DA. Alpha1-antitrypsin deficiency – a model for conformational diseases. N Engl J Med 2002; 346: 45–53.
8. Cole JW, Naj AC, O'Connell JR, et al. Neuroserpin polymorphisms and stroke risk in a biracial population: the stroke prevention in young women study. BMC Neurol 2007; 7: 37.
9. Coutelier M, Andries S, Ghariani S, et al. Neuroserpin mutation causes electrical status epilepticus of slow-wave sleep. Neurology 2008; 71: 64–66.
10. Davis RL, Shrimpton AE, Holohan PD, et al. Familial dementia caused by polymerization of mutant neuroserpin. Nature 1999; 401: 376–379.
11. Davis RL, Holohan PD, Shrimpton AE, et al. Familial encephalopathy with neuroserpin inclusion bodies. Am J Pathol 1999; 155: 1901–1913.
12. Davis RL, Shrimpton AE, Carrell RW, et al. Association between conformational mutations in neuroserpin and onset and severity of dementia. Lancet 2002; 359: 2242–2247.
13. Davies MJ, Miranda E, Roussel BD, Kaufman RJ, Marciniak SJ, Lomas DA. Neuroserpin polymers activate NF-kappaB by a calcium signaling pathway that is independent of the unfolded protein response. J Biol Chem 2009; 284: 18202–18209.
14. 1-antitrypsin. Nat Struct Biol 1996; 3: 676–681.
15. Fernandez-Monreal M, López-Atalaya JP, Benchenane K, et al. Arginine 260 of the amino-terminal domain of NR1 subunit is critical for tissue-type plasminogen activator-mediated enhancement of N-methyl-D-aspartate receptor signaling. J Biol Chem 2004; 279: 50850–50856.
16. Gourfinkel-An I, Duyckaerts C, Camuzat A, et al. Clinical and neuropathologic study of a French family with a mutation in the neuroserpin gene. Neurology 2007; 69: 79–83.
17. Hagen MC, Murrell JR, Delisle MB, et al. Encephalopathy with neuroserpin inclusion bodies presenting as progressive myoclonus epilepsy and associated with a novel mutation in the proteinase inhibitor 12 gene. Brain Pathol 2011; 1: 575–582.
18. Hastings GA, Coleman TA, Haudenschild CC, et al. Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurons. Implications for the regulation of motor learning and neuronal survival. J Biol Chem 1997; 272: 33062–33067.
19. Huntington JA, Whisstock JC. Molecular contortionism – on the physical limits of serpin ‘loop-sheet’ polymers. Biol Chem 2010; 391: 973–982.
20. Huntington JA, Pannu NS, Hazes B, Read RJ, Lomas DA, Carrell RW. A 26Å structure of a serpin polymer and implications for conformational disease. J Mol Biol 1999; 293: 449–455.
21. Huntington JA, Read RJ, Carrell RW. Structure of a serpin-protease complex shows inhibition by deformation. Nature 2000; 407: 923–926.
22. Kroeger H, Miranda E, MacLeod I, et al. Endoplasmic reticulum-associated degradation (ERAD) and autophagy cooperate to degrade polymerogenic mutant serpins. J Biol Chem 2009; 284: 22793–22802.
23. Krueger SR, Ghisu GP, Cinelli P, et al. Expression of neuroserpin, an inhibitor of tissue plasminogen activator, in the developing and adult nervous system of the mouse. J Neurosci 1997; 17: 8984–8996.
24. 1-antitrypsin accumulation in the liver. Nature 1992; 357: 605–607.
25. 53øPhe); further evidence for intracellular loop-sheet polymerisation. J Biol Chem 1993; 268: 15333–15335.
26. Minassian BA, Striano P, Avanzini G. Progressive Myoclonus Epilepsies: State-of-the-Art. Epileptic Disord 2016; 18(Suppl. 2): S1–S158.
27. Miranda E, Romisch K, Lomas DA. Mutants of neuroserpin that cause dementia accumulate as polymers within the endoplasmic reticulum. J Biol Chem 2004; 279: 28283–28291.
28. Miranda E, MacLeod I, Davies MJ, et al. The intracellular accumulation of polymeric neuroserpin explains the severity of the dementia FENIB. Hum Mol Genet 2008; 17: 1527–1539.
29. Nicole O, Docagne F, Ali C, et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001; 7: 59–64.
30. Osterwalder T, Contartese J, Stoeckli ET, Kuhn TB, Sonderegger P. Neuroserpin, an axonally secreted serine protease inhibitor. EMBO J 1996; 15: 2944–2953.
31. Osterwalder T, Cinelli P, Baici A, et al. The axonally secreted serine proteinase inhibitor, neuroserpin, inhibits plasminogen activators and plasmin but not thrombin. J Biol Chem 1998; 273: 2312–2321.
32. Qian Z, Gilbert ME, Colicos MA, Kandel ER, Kuhl D. Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. Nature 1993; 361: 453–457.
33. 1-antitrypsin at 2.7 Å. Structure 1996; 4: 1181–1192.
34. Sado M, Yamasaki Y, Iwanaga T, et al. Protective effect against Parkinson's disease-related insults through the activation of XBP1. Brain Res 2009; 1257: 16–24.
35. Samson AL, Nevin ST, Croucher D, et al. Tissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function. J Neurochem 2008; 107: 1091–1101.
36. Seeds NW, Basham ME, Haffke SP. Neuronal migration is retarded in mice lacking the tissue plasminogen activator gene. Proc Natl Acad Sci U S A 1999; 96: 14118–14123.
37. Singh P, Jairajpuri MA. Strand 6B deformation and residues exposure towards N-terminal end of helix B during proteinase inhibition by serpins. Bioinformation 2011; 5: 315–319.
38. Stoeckli ET, Lemkin PF, Kuhn TB, Ruegg MA, Heller M, Sonderegger P. Identification of proteins secreted from axons of embryonic dorsal-root-ganglia neurons. Eur J Biochem 1989; 180: 249–258.
39. Vincent P, Mulle C. Kainate receptors in epilepsy and excitotoxicity. Neuroscience 2009; 158: 309–323.
40. Wright HT, Scarsdale JN. Structural basis for serpin inhibitor activity. Proteins 1995; 22: 210–225.
41. Wu J, Echeverry R, Guzman J, Yepes M. Neuroserpin protects neurons from ischemia-induced plasmin-mediated cell death independently of tissue-type plasminogen activator inhibition. Am J Pathol 2010; 177: 2576–2584.
42. Yamasaki M, Sendall TJ, Pearce MC, Whisstock JC, Huntington JA. Molecular basis of alpha1-antitrypsin deficiency revealed by the structure of a domain-swapped trimer. EMBO Rep 2011; 12: 1011–1017.
43. Ye S, Cech AL, Belmares R, et al. The structure of a Michaelis serpin-protease complex. Nat Struct Biol 2001; 8: 979–983.
44. Yepes M, Sandkvist M, Wong MK, et al. Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood 2000; 96: 569–576.
45. Yepes M, Sandkvist M, Coleman TA, et al. Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent. J Clin Invest 2002; 109: 1571–1578.
46. Ying Z, Wang H, Fan H, Wang G. The endoplasmic reticulum (ER)-associated degradation system regulates aggregation and degradation of mutant neuroserpin. J Biol Chem 2011; 286: 20835–20844.